CRISPR Therapeutics’ gene-editing treatments are highly customized and shockingly expensive. The market is watching to see if the underlying science can be applied to treat many diseases. The company ...

CRISPR is a gene-editing tool that acts like “molecular scissors,” but using it on cancer is complex. The technology’s biggest impact so far is in research labs, helping scientists understand how ...

CRISPR Therapeutics AG stock has surged nearly 90% since my Buy call in early May, reaching its highest value since February 2024. The rally builds on the historic approval of Casgevy, a gene editing ...

What if a heart attack and lifetime of statin drugs could be avoided with a one-time, two-hour infusion? Kiran Musunuru, a University of Pennsylvania cardiologist and leading gene-editing researcher, ...

On the heels of its role in a historic medical milestone, Coralville-based Integrated DNA Technologies (IDT) announced the expansion of its end-to-end CRISPR portfolio to support faster development of ...

CRISPR reports early data for CTX310, showing major drops in triglycerides and LDL. Analysts maintain mixed ratings on the stock, with price targets ranging from $30 to $120. September’s volatility ...

Personalized CRISPR cures for children born with rare genetic diseases are now a step closer to being more widely available. Today, the Chan Zuckerberg Initiative (CZI) and the Innovative Genomics ...

CRISPR Therapeutics is a biotech company that borrows its name from the groundbreaking gene editing technology CRISPR. As of last year, the company has earned FDA approval for a CRISPR-based treatment ...